Theranostics and how it works

Theranostics is a treatment using diagnostic imaging to identify if target receptors are present on cancer cells, followed by precision radiation treatment that target these receptors.

Theranostics

Who may benefit?

Theranostics can be used to treat cancers that have spread (metastasised), or where cancer is advanced and/or hasn’t responded to other treatments.

While in the future theranostics may be used for different cancers, to date most experience and success has been in metastatic prostate cancer and neuroendocrine tumours.

Metastatic prostate cancer

How it works

Theranostics is a personalised approach to treating cancer, using both diagnosis and therapy tools as part of the treatment.

Theranostics uses PET scan imaging (a special type of scan) to see if specific targets, known as tumour receptors, are present on tumour cells. If these targets are present and visible on the scan, a radioactive drug is used to treat the tumours. The drug is given as an injection and selectively targets the tumour cells while avoiding healthy areas. Most of the radioactive drug that doesn’t reach the target is quickly passed out of the body.

Limited clinical trial evidence is available for the use of theranostics in prostate cancer and the treatment has not yet been reviewed by the Australian Medicines Regulator – The Therapeutic Goods Administration (TGA). Access to treatment is authorised via the TGA Special Access Scheme, a scheme for compassionate access to medicines before registration. It is an out of pocket expense for patients as theranostics is not currently covered by Medicare or private health insurance.

Make an enquiry about theranostics

You can also contact us by calling +61 8 9438 8500.
Make an enquiry

Types of theranostics treatments we offer

  1. Treatment for advanced prostate cancer

    Lutetium-177 PSMA therapy (Lu-PSMA) is a new treatment for advanced prostate cancer. It delivers high doses of targeted radiation to the cancer sites. It’s used to specifically target the abnormal cells while limiting damage to surrounding healthy tissue .

    Learn more

  2. Treatment for advanced neuroendocrine tumours

    Lutetium-177 Octreotate therapy (Lu-Octreotate) is a treatment for advanced neuroendocrine tumours (NETs) or carcinoids.

    It delivers high doses of targeted radiation to the cancer sites. It’s used to specifically target the abnormal cells while limiting damage to surrounding healthy tissue. This therapy has been used for almost 20 years in this tumour type and is now approved for the treatment of progressive advanced neuroendocrine tumours in Europe and the USA.

    Learn more

Theranostics patient journey

What to expect:

Before treatment commences, your Nuclear Medicine Physician will explain the treatment process, treatment options and any potential side effects. You will receive a care plan tailored to your needs.

Tips

It is a good idea to bring someone with you to the initial appointment and keep a journal to help you remember what the doctor says.

What to expect:

Any out of pocket costs associated with your treatment will be discussed with you in a clear and simple way before you commence treatment.

Tips

Please feel free to ask questions. Again, you can bring someone with you and write notes in a journal.

 

What to expect:

In order to develop your treatment plan, you will be required to attend a few appointments.
These will include a visit to an imaging department and pathology centre for your blood tests.

Tips

You will be provided with these request forms at the initial consult or with your treatment plan.

 

What to expect:

Prior to receiving your cycle of treatment, your Nuclear medical Medicine Physician will review your results and confirm your treatment plan.

Tips

It’s normal to feel anxious. Let the team know how you are feeling.

What to expect:

A nurse will assess your overall health status.

You will be given a tour of the department and an overview of what to expect.

Tips

Please feel free to ask any questions health related or otherwise.

What to expect:

A nuclear medicine technologist or nuclear medicine physician will deliver your treatment via an injection and monitor you regularly. A nurse will check that you are hydrated throughout the day by ensuring you have enough liquids or may put you on a drip if necessary. The treatment will last approximately 4 hours.

Tips

You may be in the theranostics chair for a few hours so bring a book or iPad to help pass the time.

Our theranostic specialists

A/Prof David Macfarlane

Nuclear Medicine Physician

David developed an enduring interest in radiopharmaceutical therapy and oncologic nuclear medicine during his Fellowship at the University of Michigan, Ann Arbor. He joined the GenesisCare team to pursue his interest in Theranostics after serving as Deputy Director of Nuclear Medicine at Royal Brisbane Hospital.

A/Prof Nat Lenzo

Nuclear Medicine Physician

Currently, Nat is an associate clinical professor at the University of Western Australia, fellow of health sciences at Macquarie University Hospital in Sydney, consultant nuclear physician at Fiona Stanley Hospital, and general physician at St John of God Hospital Murdoch.

Dr Brett Sounness

Nuclear Medicine Physician

Brett has an interest in Dementia imaging with extensive experience in MRI, SPECT and PET dementia imaging. He was the driving force at SCR behind amyloid imaging at the Gold Coast.

We currently have two centres in Australia offering theranostics treatment for our patients. Visit our centre page and filter by theranostics for more information.

Visit Hollywood Private Hospital, WA

Visit Hurstville, NSW
Our centres